RESUMEN
Glioma patients constitute the greatest percentage of depressed neoplasm patients. These patients often require antidepressant treatment, but the effect of antidepressant drugs on glioma cells requires further evaluation. In the present study, we evaluated the effect of trifluoperazine (TFP) on the proliferation and apoptosis of glioma cells. Transcriptomic and bioinformatics analysis results suggested that antidepressant drugs, especially TFP, may upregulate the drug-resistant ability of glioma cells. A low concentration of TFP upregulated the viability of glioma cells. Colony formation and EdU assays confirmed that TFP treatment accelerates glioma cell proliferation, but no significant difference was found in the cell cycle distribution of glioma cells after treatment with TFP or control. Flow cytometry and TUNEL staining results suggested that TFP treatment decreased apoptosis in glioma cells. In addition, TFP treatment downregulated the intracellular Ca2+ concentration of glioma cells. In vivo experimental results indicated that TFP treatment promoted proliferation and reduced apoptosis in xenograft tumours in nude mice. Taken together, our results suggest that a low concentration of TFP promotes proliferation and reduces apoptosis in glioma cells both in vitro and in vivo. The potential harmful effects of antidepressant drugs on gliomas require further evaluation before their use in glioma patients.
Asunto(s)
Antidepresivos/efectos adversos , Biomarcadores de Tumor/genética , Calcio/metabolismo , Depresión/tratamiento farmacológico , Neuroglía/efectos de los fármacos , Trifluoperazina/efectos adversos , Animales , Apoptosis/efectos de los fármacos , Apoptosis/genética , Biomarcadores de Tumor/metabolismo , Neoplasias Encefálicas/complicaciones , Neoplasias Encefálicas/genética , Neoplasias Encefálicas/patología , Calcio/farmacología , Ciclo Celular/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Depresión/complicaciones , Depresión/genética , Depresión/patología , Glioma/complicaciones , Glioma/genética , Glioma/patología , Xenoinjertos , Humanos , Antígeno Ki-67/genética , Antígeno Ki-67/metabolismo , Masculino , Ratones , Ratones Desnudos , Neuroglía/metabolismo , Neuroglía/patología , Antígeno Nuclear de Célula en Proliferación/genética , Antígeno Nuclear de Célula en Proliferación/metabolismo , Carga Tumoral/efectos de los fármacosRESUMEN
BACKGROUND: Haloperidol is worldwide one of the most frequently used antipsychotic drugs with a very high market share. Previous narrative, unsystematic reviews found no differences in terms of efficacy between the various first-generation ("conventional", "typical") antipsychotic agents. This established the unproven psychopharmacological assumption of a comparable efficacy between the first-generation antipsychotic compounds codified in textbooks and treatment guidelines. Because this assumption contrasts with the clinical impression, a high-quality systematic review appeared highly necessary. OBJECTIVES: To compare the efficacy, acceptability, and tolerability of haloperidol with other first-generation antipsychotics in schizophrenia and schizophrenia-like psychosis. SEARCH METHODS: In October 2011 and July 2012, we searched the Cochrane Schizophrenia Group's Trials Register, which is based on regular searches of CINAHL, BIOSIS, AMED, EMBASE, PubMed, MEDLINE, PsycINFO, and registries of clinical trials. To identify further relevant publications, we screened the references of all included studies and contacted the manufacturers of haloperidol for further relevant trials and missing information on identified studies. Furthermore, we contacted the corresponding authors of all included trials for missing data. SELECTION CRITERIA: We included all randomised controlled trials (RCTs) that compared oral haloperidol with another oral first-generation antipsychotic drug (with the exception of the low-potency antipsychotics chlorpromazine, chlorprothixene, levopromazine, mesoridazine, perazine, prochlorpromazine, and thioridazine) in schizophrenia and schizophrenia-like psychosis. Clinically important response to treatment was defined as the primary outcome. Secondary outcomes were global state, mental state, behaviour, overall acceptability (measured by the number of participants leaving the study early due to any reason), overall efficacy (attrition due to inefficacy of treatment), overall tolerability (attrition due to adverse events), and specific adverse effects. DATA COLLECTION AND ANALYSIS: At least two review authors independently extracted data from the included trials. The methodological quality of the included studies was assessed using The Cochrane Collaboration`s 'Risk of bias' tool.We analysed dichotomous outcomes with risk ratios (RR) and continuous outcomes with mean differences (MD), both with the associated 95% confidence intervals (CI). All analyses were based on a random-effects model and we preferably used data on an intention-to-treat basis where possible. MAIN RESULTS: The systematic review currently includes 63 randomised trials with 3675 participants. Bromperidol (n = 9), loxapine (n = 7), and trifluoperazine (n = 6) were the most frequently administered antipsychotics comparator to haloperidol. The included studies were published between 1962 and 1993, were characterised by small sample sizes (mean: 58 participants, range from 18 to 206) and the predefined outcomes were often incompletely reported. All results for the main outcomes were based on very low or low quality data. In many trials the mechanism of randomisation, allocation, and blinding was frequently not reported. In short-term studies (up to 12 weeks), there was no clear evidence of a difference between haloperidol and the pooled group of the other first-generation antipsychotic agents in terms of the primary outcome "clinically important response to treatment" (40 RCTs, n = 2132, RR 0.93 CI 0.87 to 1.00). In the medium-term trials, haloperidol may be less effective than the other first-generation antipsychotic group but this evidence is based on only one trial (1 RCT, n = 80, RR 0.51 CI 0.37 to 0.69).Based on limited evidence, haloperidol alleviated more positive symptoms of schizophrenia than the other antipsychotic drugs. There were no statistically significant between-group differences in global state, other mental state outcomes, behaviour, leaving the study early due to any reason, due to inefficacy, as well as due to adverse effects. The only statistically significant difference in specific side effects was that haloperidol produced less akathisia in the medium term. AUTHORS' CONCLUSIONS: The findings of the meta-analytic calculations support the statements of previous narrative, unsystematic reviews suggesting comparable efficacy of first-generation antipsychotics. In efficacy-related outcomes, there was no clear evidence of a difference between the prototypal drug haloperidol and other, mainly high-potency first-generation antipsychotics. Additionally, we demonstrated that haloperidol is characterised by a similar risk profile compared to the other first-generation antipsychotic compounds. The only statistically significant difference in specific side effects was that haloperidol produced less akathisia in the medium term. The results were limited by the low methodological quality in many of the included original studies. Data for the main results were low or very low quality. Therefore, future clinical trials with high methodological quality are required.
Asunto(s)
Antipsicóticos/uso terapéutico , Haloperidol/uso terapéutico , Trastornos Psicóticos/tratamiento farmacológico , Esquizofrenia/tratamiento farmacológico , Administración Oral , Antipsicóticos/efectos adversos , Haloperidol/efectos adversos , Haloperidol/análogos & derivados , Humanos , Loxapina/efectos adversos , Loxapina/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como Asunto , Trifluoperazina/efectos adversos , Trifluoperazina/uso terapéuticoRESUMEN
BACKGROUND: Antipsychotic drugs are the core treatment for schizophrenia. Treatment guidelines state that there is no difference in efficacy between any other antipsychotic compounds, however, low-potency antipsychotic drugs are often perceived as less efficacious than high-potency compounds by clinicians, and they also seem to differ in their side-effects. OBJECTIVES: To review the effects in response to treatment of trifluoperazine and low-potency antipsychotics for people with schizophrenia. SEARCH METHODS: We searched the Cochrane Schizophrenia Group's Trials Register (November 2010). SELECTION CRITERIA: We included all randomised trials comparing trifluoperazine with first-generation low-potency antipsychotic drugs for people with schizophrenia or schizophrenia-like psychosis. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. MAIN RESULTS: The review currently includes seven randomised trials involving 422 participants that compared trifluoperazine with low-potency antipsychotic drugs. The size of the included studies was between 20 and 157 participants with a study length between four and 52 weeks. Overall, sequence generation, allocation procedures and blinding were poorly reported. Trifluoperazine was not significantly different from low-potency antipsychotic drugs in terms of response to treatment (trifluoperazine 26%, low-potency drug 27%, 3 RCTs, n = 120, RR 0.96 CI 0.59 to 1.56, moderate quality evidence). There was also no significant difference in acceptability of treatment with equivocal number of participants leaving the studies early due to any reason (trifluoperazine 20%, low-potency antipsychotics 16%, 3 RCTs, n = 239, RR 1.25, CI 0.72 to 2.17,low quality evidence). There was no significant difference in numbers with at least one adverse effect (trifluoperazine 60%, low-potency antipsychotics 38%, 1 RCT, n = 60, RR 1.60, CI 0.94 to 2.74, moderate quality evidence). However, at least one movement disorder was significantly more frequent in the trifluoperazine group (trifluoperazine 23%, low-potency antipsychotics 13%, 2 RCTs, n = 123, RR 2.08 CI 0.78 to 5.55, very low quality evidence) as well as incoordination (trifluoperazine 20%, low-potency antipsychotics 5%, 1 RCT, n = 60, RR 7.00, CI 1.60 to 30.66) and rigor (trifluoperazine 45%, low-potency antipsychotics 10%, 1 RCT, n = 60, RR 4.50, CI 1.58 to 12.84). No data were available for other outcomes of interest death, sedation and quality of life. AUTHORS' CONCLUSIONS: The results did not show a difference in efficacy between trifluoperazine and low-potency antipsychotics. Trifluoperazine produced more movement disorders. The number of randomised studies as well as their quality is low, the quality of evidence for outcomes of interest ranged from moderate to very low quality, so more, newer studies would be needed for conclusions about the relative effects of trifluoperazine and low-potency antipsychotics.
Asunto(s)
Antipsicóticos/uso terapéutico , Esquizofrenia/tratamiento farmacológico , Trifluoperazina/uso terapéutico , Antipsicóticos/efectos adversos , Humanos , Pacientes Desistentes del Tratamiento/estadística & datos numéricos , Ensayos Clínicos Controlados Aleatorios como Asunto , Trifluoperazina/efectos adversosRESUMEN
BACKGROUND: Trifluoperazine is a long-established high potency typical antipsychotic drug used in the treatment of schizophrenia and schizophrenia-like illnesses. OBJECTIVES: To determine absolute effects of trifluoperazine for schizophrenia and schizophrenia-like illnesses compared with placebo.To critically appraise and summarise current evidence on the resource use, cost and economic evaluation of trifluoperazine compared with placebo for schizophrenia. SEARCH METHODS: Searches of the Cochrane Schizophrenia Group's register of trials (July 2012), supplemented with handsearching, reference searching, personal communication and contact with industry. Two review authors undertook a search for economic studies using the Cochrane Schizophrenia Group's Health Economic Database (CSzGHED) on the 9th April 2013. SELECTION CRITERIA: All available clinical randomised trials involving people with schizophrenia and schizophrenia-like illnesses that compare trifluoperazine with placebo. DATA COLLECTION AND ANALYSIS: Studies for the effects of interventions were reliably selected by a review team and data were doubly independently extracted to reduce bias. We only used dichotomous data, using intention-to-treat analysis when possible. Data were estimated using risk ratio (RR) with 95% confidence intervals (CI). A 'Summary of findings' table was produced, where possible, for each primary outcome using GRADE. Economic studies were searched and reliably selected by review authors (VF and SS) to provide an economic summary of available data. Where no relevant economic studies were eligible for inclusion, the economic review team valued the already-included effectiveness outcome data to provide a rudimentary economic summary. MAIN RESULTS: This review included 10 studies with a total number of 686 participants featuring in 20 different outcomes of interest. Overall, there was significant clinical improvement in clinical global state at medium term amongst people receiving trifluoperazine (3 RCTs, n = 417, RR 4.61, CI 1.54 to 13.84, low quality evidence) and significantly fewer people receiving trifluoperazine left the studies early due to relapse or worsening at medium term (2 RCTs, n = 381, RR 0.34, CI 0.23 to 0.49, low quality evidence). However, results were equivocal for leaving the study early at medium term for any reason (2 RCTs, n = 391, RR 0.80, CI 0.17 to 3.81, very low quality evidence) and due to severe adverse effects (2 RCTs, n = 391, RR 1.54, CI 0.56 to 4.24, very low quality evidence). Equivocal data were also found for intensified symptoms at medium term (2 RCTs, n = 80, RR 1.05, CI 0.54 to 2.05, very low quality evidence) and rates of agitation or distress again at medium term (1 RCT, n = 52, RR 2.00, CI 0.19 to 20.72, very low quality evidence). Comparison between low and high-dose trifluoperazine with placebo from a single study provided equivocal evidence of effects. For economic outcomes, we valued outcomes in GBP terms and presented them in additional tables; there was an estimated saving of £3488.3 in favour of trifluoperazine. However, numerous assumptions were made and these savings need to be interpreted in light of those assumptions. AUTHORS' CONCLUSIONS: Our results agree with existing evidence that compared to placebo, trifluoperazine is an effective antipsychotic for people with schizophrenia. Furthermore, our review provides supportive evidence that trifluoperazine increases the risk of extrapyramidal adverse effects. Although the effect sizes against placebo are similar to those observed with other agents, they are based on data from many small, pre-CONSORT trials with generally either a low or very low GRADE evidence that has limited implication for clinical practice. Large, independent trials are needed that adhere to the CONSORT statement to compare trifluoperazine with placebo used in the treatment of schizophrenia and schizophrenia-like illnesses.
Asunto(s)
Antipsicóticos/uso terapéutico , Esquizofrenia/tratamiento farmacológico , Trifluoperazina/uso terapéutico , Antipsicóticos/efectos adversos , Discinesia Inducida por Medicamentos/etiología , Humanos , Ensayos Clínicos Controlados Aleatorios como Asunto , Trifluoperazina/efectos adversosRESUMEN
Recent evidence of neuropathic pain among adults with sickle cell disease (SCD) reveals a need for adjuvant analgesic treatments for these patients. Ca(2+)/calmodulin protein kinase IIα (CaMKIIα) has a known role in neuropathic pain and trifluoperazine is a potent CaMKIIα inhibitor. The study aim was to determine trifluoperazine's acute effects, primarily on adverse effects and secondarily on pain intensity reduction, in adults with SCD. In a phase I, open-label study of 6 doses of trifluoperazine (0.5, 1, 2, 5, 7.5, 10mg), we obtained 7-hourly and 24-h repeated measures of adverse effects, pain intensity, and supplemental opioid analgesics in 18 adults with SCD (18 hemoglobin SS disease, 15 women, average age 35.8±8.9 years, ranged 23-53) each of whom received a single dose. Data were analyzed with descriptive statistics. Subjects reported moderate to severe sedative effects at 7.5 and 10mg doses, respectively. Eight subjects reported 50% reduction in chronic pain without severe sedation or supplemental opioid analgesics; one of these subjects had dystonia 24.5h after the 10mg dose. The analgesic effect lasted for at least 24h in 3 subjects. Sedation resolved with caffeine and dystonia resolved with diphenhydramine. Adults with SCD experienced minimal adverse effects at doses under 10mg. In this molecular mechanism-driven translational study, trifluoperazine shows promise as an analgesic drug that is worthy of further testing in a randomized controlled study of adults with SCD starting at a dose of 1mg in repeated doses to determine long-term adverse and analgesic effects.
Asunto(s)
Analgésicos/uso terapéutico , Anemia de Células Falciformes/tratamiento farmacológico , Neuralgia/tratamiento farmacológico , Trifluoperazina/uso terapéutico , Adulto , Analgésicos/efectos adversos , Proteína Quinasa Tipo 2 Dependiente de Calcio Calmodulina , Femenino , Humanos , Masculino , Persona de Mediana Edad , Trifluoperazina/efectos adversos , Adulto JovenAsunto(s)
Antipsicóticos/efectos adversos , Terapia Electroconvulsiva , Enfermedad de Parkinson Secundaria/inducido químicamente , Enfermedad de Parkinson Secundaria/terapia , Trifluoperazina/efectos adversos , Antipsicóticos/uso terapéutico , Discinesia Inducida por Medicamentos/fisiopatología , Humanos , Masculino , Persona de Mediana Edad , Pruebas Neuropsicológicas , Escalas de Valoración Psiquiátrica , Esquizofrenia Paranoide/complicaciones , Esquizofrenia Paranoide/tratamiento farmacológico , Resultado del Tratamiento , Trifluoperazina/uso terapéuticoRESUMEN
OBJECTIVE: The objective of this study is to determine the prevalence of metabolic syndrome among schizophrenia patients receiving antipsychotic monotherapy in Malaysia. METHOD: A cross-sectional study was conducted at multiple centres between June 2008 and September 2011. Two hundred and five patients who fulfilled the DSM IV-TR diagnostic criteria for schizophrenia and who had been on antipsychotic medication for at least one year, were screened for metabolic syndrome. Patients receiving a mood stabilizer were excluded from the study. Metabolic syndrome was defined by using the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Treatment Panel III (ATP III) modified for Asian waist circumference. RESULTS: In the first-generation antipsychotic (FGA) group, the highest prevalence of metabolic syndrome was among patients treated with trifluoperazine and flupenthixol decanoate (66.7% each). For the second-generation antipsychotic (SGA) group, the highest prevalence of metabolic syndrome was among patients treated with clozapine (66.7%). The component with the highest prevalence in metabolic syndrome was waist circumference in both FGA and SGA groups except for aripiprazole in SGA. CONCLUSION: The prevalence of metabolic syndrome in schizophrenia patients receiving antipsychotic monotherapy in Malaysia was very high. Intervention measures are urgently needed to combat these problems.
Asunto(s)
Antipsicóticos/uso terapéutico , Síndrome Metabólico/epidemiología , Esquizofrenia/tratamiento farmacológico , Adulto , Antipsicóticos/efectos adversos , Aripiprazol , Clozapina/efectos adversos , Clozapina/uso terapéutico , Estudios Transversales , Femenino , Flupentixol/efectos adversos , Flupentixol/uso terapéutico , Humanos , Malasia/epidemiología , Masculino , Síndrome Metabólico/inducido químicamente , Síndrome Metabólico/etiología , Persona de Mediana Edad , Piperazinas/efectos adversos , Piperazinas/uso terapéutico , Quinolonas/efectos adversos , Quinolonas/uso terapéutico , Esquizofrenia/complicaciones , Trifluoperazina/efectos adversos , Trifluoperazina/uso terapéutico , Circunferencia de la Cintura , Adulto JovenRESUMEN
OBJECTIVE: This study compares the efficacy of risperidone and olanzapine to that of first-generation antipsychotics (FGAs) in patients with schizophrenia, who failed to show a response to initial trials of FGAs. METHOD: This study was an 8-week treatment, randomized, rater-blind, active-control study with 3 treatment arms. 48 patients, who showed inadequate response to 1 FGA, were enrolled and randomized into risperidone, olanzapine, or FGA (haloperidol or trifluoperazine) groups. They were blindly assessed with the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impression Scale-Severity, and the Extrapyramidal Symptom Rating Scale (ESRS) at baseline and biweekly. RESULTS: All 3 groups demonstrated a significant decrease in the PANSS total, positive, and general scores from baseline to endpoint (p-values range from 0.003 to 0.021). There were no significant differences among the 3 groups in score changes. The olanzapine group had significant score reductions than the risperidone and FGAs groups in terms of the ESRS subjective total score and did not experience a significant increase in the dose of anticholinergics. The FGA group demonstrated that extrapyramidal syndrome (EPS) worsened under an increased dosage of anti-EPS drugs. Olanzapine was associated with significant body weight gain (2.69 ± 4.0 kg, p=0.026), but there were no significant group differences on weight gain. CONCLUSIONS: Haloperidol or trifluoperazine demonstrated similar efficacy as risperidone or olanzapine for patients with schizophrenia who had failed their first trial with a FGA. Related double-blind, fixed dose studies with a larger sample size are needed to confirm the results of our study.
Asunto(s)
Antipsicóticos/uso terapéutico , Benzodiazepinas/uso terapéutico , Resistencia a Medicamentos/efectos de los fármacos , Haloperidol/farmacología , Risperidona/uso terapéutico , Esquizofrenia/tratamiento farmacológico , Trifluoperazina/farmacología , Adolescente , Adulto , Anciano , Antipsicóticos/efectos adversos , Benzodiazepinas/efectos adversos , Femenino , Haloperidol/efectos adversos , Haloperidol/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Olanzapina , Escalas de Valoración Psiquiátrica/estadística & datos numéricos , Risperidona/efectos adversos , Esquizofrenia/diagnóstico , Método Simple Ciego , Trifluoperazina/efectos adversos , Trifluoperazina/uso terapéuticoAsunto(s)
Adenoma/complicaciones , Hiperprolactinemia/complicaciones , Neoplasias Hipofisarias/complicaciones , Esquizofrenia/tratamiento farmacológico , Adenoma/patología , Adulto , Antipsicóticos/efectos adversos , Antipsicóticos/uso terapéutico , Aripiprazol , Benzodiazepinas/efectos adversos , Benzodiazepinas/uso terapéutico , Bromocriptina/efectos adversos , Bromocriptina/uso terapéutico , Antagonistas de Dopamina/efectos adversos , Antagonistas de Dopamina/uso terapéutico , Femenino , Antagonistas de Hormonas/efectos adversos , Antagonistas de Hormonas/uso terapéutico , Humanos , Hiperprolactinemia/etiología , Olanzapina , Piperazinas/efectos adversos , Piperazinas/uso terapéutico , Neoplasias Hipofisarias/patología , Quinolonas/efectos adversos , Quinolonas/uso terapéutico , Risperidona/efectos adversos , Risperidona/uso terapéutico , Esquizofrenia/etiología , Esquizofrenia/patología , Antagonistas de la Serotonina/efectos adversos , Antagonistas de la Serotonina/uso terapéutico , Trifluoperazina/efectos adversos , Trifluoperazina/uso terapéuticoRESUMEN
This naturalistic retrospective study aims to compare effectiveness of a second-generation antipsychotic medication, risperidone, with first-generation antipsychotic medications (haloperidol and trifluoperazine) in an Asian population with first-episode schizophrenia-spectrum disorders. A total of 261 patients were assessed for time to discontinuation for any reason and specific reasons of discontinuation, controlling for baseline differences between groups. Some 90% of patients discontinued their antipsychotic medications before 18 months. Median time to discontinuation for any reason in risperidone was 69 days versus first-generation antipsychotic medications of 27 days. Specifically, the risperidone group had a longer time to discontinuation for any reason than haloperidol (HR = 0.61, p = 0.005) and trifluoperazine groups (HR = 0.63, p = 0.03), as well as a longer time to discontinuation due to intolerability of side effects than haloperidol (HR = 0.50, p = 0.008) and trifluoperazine groups (HR = 0.26, p = 0.001). There were no significant differences between medications for time to discontinuation due to lack of efficacy, patient's/family's decisions or other reasons. We conclude that there is a very high rate of discontinuation of the initial antipsychotic medications for various reasons, with risperidone having an overall longer time to discontinuation compared with first-generation antipsychotic medications.
Asunto(s)
Antipsicóticos/uso terapéutico , Risperidona/uso terapéutico , Esquizofrenia/tratamiento farmacológico , Adolescente , Adulto , Antipsicóticos/efectos adversos , Pueblo Asiatico , Femenino , Haloperidol/efectos adversos , Haloperidol/uso terapéutico , Humanos , Estimación de Kaplan-Meier , Masculino , Escalas de Valoración Psiquiátrica , Estudios Retrospectivos , Risperidona/efectos adversos , Factores Socioeconómicos , Resultado del Tratamiento , Trifluoperazina/efectos adversos , Trifluoperazina/uso terapéutico , Adulto JovenRESUMEN
Inhibition of mitochondrial permeability transition (mPT) has emerged as a promising approach for neuroprotection and development of well-tolerated mPT inhibitors with favorable blood-brain barrier penetration is highly warranted. In a recent study, 28 clinically available drugs with a common heterocyclic structure were identified as mPT inhibitors e.g. trifluoperazine, promethazine and nortriptyline. In addition, neuroprotection by structurally unrelated drugs e.g. neurosteroids, 4-hydroxy-tamoxifen and trimetazidine has been attributed to direct inhibition of mPT. The regulation of mPT is complex and highly dependent on the prevailing experimental conditions. Several features of mPT, such as swelling, depolarization or NADH oxidation, can also occur independently of the mPT phenomenon. Here, in isolated rodent brain-derived and human liver mitochondria, we re-evaluate drugs promoted as potent mPT inhibitors. We address the definition of an mPT inhibitor and present strategies to reliably detect mPT inhibition in vitro. Surprisingly, none of the 12 compounds tested displayed convincing mPT inhibition or effects comparable to cyclophilin D inhibition by the non-immunosuppressive cyclophilin inhibitor D-MeAla(3)-EtVal(4)-Cyclosporin (Debio 025). Propofol and 2-aminoethoxydiphenyl borate (2-APB) inhibited swelling in de-energized mitochondria but did not increase calcium retention capacity (CRC). Progesterone, trifluoperazine, allopregnanolone and 4-hydroxy-tamoxifen dose-dependently reduced CRC and respiratory control and were thus toxic rather than beneficial to mitochondrial function. Interestingly, topiramate increased CRC at high concentrations likely by a mechanism separate from direct mPT inhibition. We conclude that a clinically relevant mPT inhibitor should have a mitochondrial target and increase mitochondrial calcium retention at concentrations which can be translated to human use.
Asunto(s)
Encefalopatías/metabolismo , Encéfalo/metabolismo , Calcio/metabolismo , Mitocondrias/efectos de los fármacos , Mitocondrias/metabolismo , Proteínas de Transporte de Membrana Mitocondrial/antagonistas & inhibidores , Isomerasas de Aminoácido/efectos adversos , Isomerasas de Aminoácido/farmacología , Animales , Compuestos de Boro/efectos adversos , Compuestos de Boro/farmacología , Encéfalo/efectos de los fármacos , Encefalopatías/tratamiento farmacológico , Peptidil-Prolil Isomerasa F , Ciclofilinas/efectos adversos , Ciclofilinas/farmacología , Relación Dosis-Respuesta a Droga , Humanos , Masculino , Mitocondrias Hepáticas/efectos de los fármacos , Mitocondrias Hepáticas/metabolismo , Poro de Transición de la Permeabilidad Mitocondrial , Pregnanolona/efectos adversos , Pregnanolona/farmacología , Progesterona/efectos adversos , Progesterona/farmacología , Propofol/efectos adversos , Propofol/farmacología , Ratas , Ratas Wistar , Tamoxifeno/efectos adversos , Tamoxifeno/análogos & derivados , Tamoxifeno/farmacología , Trifluoperazina/efectos adversos , Trifluoperazina/farmacología , Trimetazidina/efectos adversos , Trimetazidina/farmacologíaAsunto(s)
Antipsicóticos/historia , Industria Farmacéutica/historia , Mercadotecnía/historia , Trastornos Psicóticos/historia , Trifluoperazina/historia , Antipsicóticos/efectos adversos , Historia del Siglo XX , Humanos , Trastornos Psicóticos/tratamiento farmacológico , Trifluoperazina/efectos adversos , Estados UnidosAsunto(s)
Antipsicóticos/efectos adversos , Síndrome de Abstinencia a Sustancias/psicología , Trifluoperazina/efectos adversos , Anciano , Antidepresivos de Segunda Generación/uso terapéutico , Antipsicóticos/uso terapéutico , Citalopram/uso terapéutico , Trastorno Depresivo/complicaciones , Trastorno Depresivo/tratamiento farmacológico , Humanos , Masculino , Trifluoperazina/uso terapéuticoRESUMEN
We carried out a retrospective descriptive study to determine prevalence and risk factors for tardive dyskinesia (TD) among psychotic patients treated with conventional neuroleptics in 4 centres in Saudi Arabia. Records of patients who had been taking > or = 1 conventional neuroleptic for > or = 6 months from January 1997 to December 2000 were examined; 151 patients were included in the final analysis. Only 51 had TD; another 59 (6.8%) patients had drug-induced Parkinson disease. Duration of treatment (P < 0.001), higher doses of neuroleptics (P < 0.01) and age over 40 years (P < 0.01) were associated with TD. A statistically significant difference in prevalence was found between Arabs (23.5%) and Afro-Arabs (45.5%) (P < 0.01). Overall prevalence of TD among psychotic patients was 5.9%.
Asunto(s)
Antipsicóticos/efectos adversos , Árabes/estadística & datos numéricos , Discinesia Inducida por Medicamentos/epidemiología , Discinesia Inducida por Medicamentos/etiología , Trastornos Psicóticos/tratamiento farmacológico , Adulto , África/etnología , Distribución por Edad , Población Negra/estadística & datos numéricos , Clorpromazina/efectos adversos , Estudios Transversales , Discinesia Inducida por Medicamentos/diagnóstico , Femenino , Haloperidol/efectos adversos , Humanos , Masculino , Vigilancia de la Población , Prevalencia , Estudios Retrospectivos , Factores de Riesgo , Arabia Saudita/epidemiología , Distribución por Sexo , Factores Socioeconómicos , Factores de Tiempo , Trifluoperazina/efectos adversosRESUMEN
The association of hyperglycaemia and weight gain with the use of atypical antipsychotics has been documented. However, there is still not enough data from India. The fact that Indian patients usually have a lower body weight compared to European and American counterparts makes it difficult to extrapolate available data to the Indian context. The purpose of this study is: (a) To compare the prevalence of hyperglycaemia in schizophrenic patients taking olanzapine with those taking typical antipsychotics, and (b) to follow-up non-diabetic, non-obese schizophrenics on a stable regimen of antipsychotic monotherapy and determine the proportion of patients who develop weight gain, diabetes or impaired glucose tolerance; comparing the effects of olanzapine versus typical antipsychotics. Fifty-five schizophrenic patients attending psychiatry outpatients' department and on stable antipsychotic monotherapy for at least 6 weeks were included in the study. Those with a family or personal history of diabetes were excluded. There were 28 cases on olanzapine and 27 on either haloperidol or trifluoperazine. Fasting blood glucose estimation and body-mass Index (BMI) were recorded at baseline, at 6 weeks, and at 12 weeks. The two groups were comparable with respect to age, genderwise composition, and duration of illness. There was no significant difference in baseline glycaemic status or BMI. At the end of 12 weeks, olanzapine was not associated with any significant change in body weight, BMI or plasma fasting glucose. Duration of use of antipsychotic emerged as the only statistically significant risk factor for developing hyperglycaemia across both groups.
Asunto(s)
Antipsicóticos/efectos adversos , Diabetes Mellitus/inducido químicamente , Hiperglucemia/inducido químicamente , Obesidad/inducido químicamente , Esquizofrenia/tratamiento farmacológico , Inhibidores Selectivos de la Recaptación de Serotonina/efectos adversos , Adulto , Antipsicóticos/clasificación , Benzodiazepinas/efectos adversos , Glucemia/efectos de los fármacos , Índice de Masa Corporal , Peso Corporal , Femenino , Haloperidol/efectos adversos , Humanos , India , Masculino , Olanzapina , Estudios Prospectivos , Factores de Tiempo , Trifluoperazina/efectos adversosAsunto(s)
Alendronato/uso terapéutico , Antipsicóticos/efectos adversos , Enfermedades Óseas Metabólicas/inducido químicamente , Enfermedades Óseas Metabólicas/tratamiento farmacológico , Haloperidol/efectos adversos , Esquizofrenia Paranoide/tratamiento farmacológico , Trifluoperazina/efectos adversos , Femenino , Humanos , Persona de Mediana EdadAsunto(s)
Mianserina/efectos adversos , Complicaciones del Embarazo/tratamiento farmacológico , Embarazo/psicología , Adulto , Antidepresivos Tricíclicos/administración & dosificación , Antidepresivos Tricíclicos/efectos adversos , Ansiedad/tratamiento farmacológico , Depresión/tratamiento farmacológico , Quimioterapia Combinada , Femenino , Estudios de Seguimiento , Humanos , Mianserina/administración & dosificación , Mianserina/análogos & derivados , Mirtazapina , Resultado del Embarazo , Trifluoperazina/efectos adversos , Trifluoperazina/uso terapéuticoRESUMEN
Neuroleptic malignant syndrome (NMS) is a life-threatening reaction often related to neuroleptic drugs, characterized by rigidity, hyperthermia, altered consciousness, and fluctuating blood pressure. We present a case of NMS that followed a doubled oral dose of a drug compound: tranylcypromine sulfate, a monoamine oxidase inhibitor, and trifluoperazine (neuroleptic). The case was complicated by rhabdomyolisis and disseminated intravascular coagulation. It was treated successfully with dantrolene sodium and generous fluid therapy without using neuromuscular blocking agents or dopamine agonists.